Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC): Kevin C. Tang’s Tang Capital Partners LP filed an amended 13D.
You can check out Tang Capital Management’s latest holdings and filings here.
Please follow Tang Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Tang Capital Management or update its stock holdings.
Follow Kevin C. Tang's Tang Capital Management
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Tang Capital Partners||0||336,747||0||336,747||336,747||2.8%|
|Tang Capital Management||0||336,747||0||336,747||336,747||2.8%|
|Kevin C. Tang||0||336,747||0||336,747||336,747||2.8%|
Page 1 of 7 – SEC Filing
Cyclacel Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
Tang Capital Management, LLC
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 16, 2017
(Date of Event which Requires Filing of this Statement)